Nasdaq · Healthcare
VERTEX PHARMACEUTICALS INC / MA (VRTX)
As-reported financials and recent SEC filings for VERTEX PHARMACEUTICALS INC / MA, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$12.00B
Net income
$3.95B
Net margin
32.9%
Diluted EPS
$15.32
ROE
21.2%
P/E (TTM)
26.4×
Market cap
$112.92B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B |
| Gross profit | $10.35B | $9.49B | $8.61B | $7.85B | $6.67B |
| Operating income | $4.17B | $-232.9M | $3.83B | $4.31B | $2.78B |
| Net income | $3.95B | $-535.6M | $3.62B | $3.32B | $2.34B |
| Diluted EPS | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-05
View on EDGAR →42026-06-03
View on EDGAR →42026-06-02
View on EDGAR →1442026-06-01
View on EDGAR →1442026-05-29
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →1442026-05-15
View on EDGAR →Go deeper on VRTX
Search VERTEX PHARMACEUTICALS INC / MA’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.